logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Navneet Upadhyay

Eli Lilly and Company
H指数:7
被引数:238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predicted 10-year cardiovascular disease risk reduction with tirzepatide use over 3 years for primary prevention of cardiovascular disease in obesity

使用替尔泊肽3年对肥胖患者心血管疾病一级预防中10年心血管疾病风险预测的降低

European Journal of Preventive Cardiology
IF7.5
2026-08-100
OAAI
Naveed Sattar; Mamas Mamas; Runjia Li; Luis-Emilio García-Pérez; Kevin L Chen; Navneet Upadhyay; Leonard Glass; Rachel L Batterham; Georgios K Dimitriadis; Hong Liu-Seifert; null
Treatment sequencing patterns and healthcare resource utilization in patients with Crohn's disease initiating biologics: a 3-year retrospective claims-based analysis

克罗恩病患者启动生物制剂治疗的治疗顺序模式与医疗资源利用：一项基于3年回顾性索赔数据的分析

CURRENT MEDICAL RESEARCH AND OPINION
IF2.2
2025-11-010
PRE
Gorritz, Magdaliz; Upadhyay, Navneet; Tuly, Rifat; Fisher, Deborah A.; Kariuki, Wanjiku; Bires, Nicholas; Vadhariya, Aisha; Hull, Michael; Naik, Amar
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

替热帕德对射血分数保留和肥胖的心力衰竭患者循环超负荷和终末器官损害的影响: SUMMIT试验的二次分析

NATURE MEDICINE
IF50
2024-11-170
OAAI
Borlaug, Barry A.; Zile, Michael R.; Kramer, Christopher M.; Baum, Seth J.; Hurt, Karla; Litwin, Sheldon E.; Murakami, Masahiro; Ou, Yang; Upadhyay, Navneet; Packer, Milton

研究方向

暂未获取到该数据
R
Rajender R. Aparasu
H 指数:38论文数:409被引数:4,916
P
Paul J. Rowan
H 指数:16论文数:82被引数:1,300
M
Marc L. Fleming
H 指数:19论文数:113被引数:965
R
Rajesh Balkrishnan
H 指数:47论文数:269被引数:9,742
A
Ali Mojebi
H 指数:7论文数:37被引数:172
C
Christopher M. Black
H 指数:26论文数:197被引数:2,090
K
Karthik Ramakrishnan
H 指数:4论文数:22被引数:64
D
Deborah A. Fisher
H 指数:41论文数:228被引数:9,705
H
Hua Chen
H 指数:0论文数:2被引数:9
H 指数:0论文数:27被引数:0